Savara (NASDAQ:SVRA) Posts Quarterly Earnings Results, Hits Expectations

Savara (NASDAQ:SVRA) announced its earnings results on Tuesday. The company reported ($0.11) EPS for the quarter, meeting the consensus estimate of ($0.11), Zacks reports.

Savara Trading Down 15.1 %

NASDAQ:SVRA opened at $3.25 on Thursday. The firm’s 50 day moving average is $3.96 and its 200 day moving average is $4.22. Savara has a 12 month low of $3.24 and a 12 month high of $5.70. The company has a quick ratio of 11.31, a current ratio of 11.31 and a debt-to-equity ratio of 0.26.

Analysts Set New Price Targets

Several equities research analysts have commented on the stock. JMP Securities reiterated a “market outperform” rating and issued a $9.00 price objective on shares of Savara in a research note on Tuesday, October 1st. HC Wainwright decreased their price target on Savara from $10.00 to $6.00 and set a “buy” rating for the company in a research report on Wednesday. Finally, Evercore ISI restated an “in-line” rating and issued a $5.00 price objective (down previously from $7.00) on shares of Savara in a research note on Wednesday. One investment analyst has rated the stock with a hold rating and five have given a buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $10.17.

Savara Company Profile

Savara Inc, formerly Mast Therapeutics, Inc, is a clinical-stage pharmaceutical company. The Company is focused on the development and commercialization of novel therapies for the treatment of patients with rare respiratory diseases. Its pipeline includes AeroVanc, Molgradex and AIR001. AeroVanc is an inhaled formulation of vancomycin, which the Company is developing for the treatment of persistent methicillin-resistant Staphylococcus aureus, lung infection in cystic fibrosis patients.